Word: interneuron
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...about to run out, and the new formulation could be considered a novel, patentable drug. Servier approached Wurtman in the late 1970s with a proposal that he purchase the U.S. rights to dexfenfluramine. Wurtman tested the drug, found it was indeed effective and agreed. The actual purchaser would be Interneuron Pharmaceuticals, a company co-founded by Wurtman to market discoveries by M.I.T. scientists. Interneuron subsequently licensed the drug to Wyeth-Ayerst for marketing...
...Then Interneuron went after and got FDA approval--a ruling that critics charge was made with unseemly--and perhaps even unprofessional--haste. Says Lewis Seiden, a University of Chicago pharmacologist who testified before the FDA advisory committee: "The procedures were loose, to be mild about...
...that time came, however, the anti-Redux forces were missing. The meeting had been scheduled--all too conveniently, they suggest--to coincide with an international neurosciences conference in San Diego. And at the second meeting, Redux won approval by a one-vote margin. That, along with the fact that Interneuron sent a high-profile member of its board of directors, Alexander Haig, to the November meeting in what was perceived as a high-pressure lobbying effort, led to charges that Redux was moved through improperly...
...case in point, Dr. Richard J. Wurtman, an MIT professor who serves as professor of neuroendocrine regulations at the joint Harvard-MIT Health Services and Technology Division, is the co-founder and a director and adviser of Interneuron Pharmaceuticals...
Wurtman says he therefore founded the company Interneuron in 1988 with MIT as a part-owner for the sole purpose of licensing drugs for which MIT owns the patent...